AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IOVA
  4. [SCHEDULE 13G/A] Iovance Biotherapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] Iovance Biotherapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock IOVA logo
Iovance Biotherp

NASDAQ:IOVA

IOVA Rankings

#3727 Ranked by Market Cap
N/A Ranked by Dividends

IOVA Latest News

Aug 7, 2025
Iovance Biotherapeutics Reports Financial Results聽and Corporate Updates for Second Quarter and First Half 2025
Jul 24, 2025
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
Jul 18, 2025
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 15, 2025
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
Jul 14, 2025
AG真人官方-World Data Demonstrate a 49% Response Rate聽for Commercial Amtagvi庐 in Patients with Advanced Melanoma

IOVA Latest SEC Filings

Aug 7, 2025
[10-Q] Iovance Biotherapeutics, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] Iovance Biotherapeutics, Inc. Reports Material Event
Jul 29, 2025
[SCHEDULE 13G/A] Iovance Biotherapeutics, Inc. SEC Filing
Jul 15, 2025
[8-K] Iovance Biotherapeutics, Inc. Reports Material Event
Jul 10, 2025
[Form 3] Iovance Biotherapeutics, Inc. Initial Statement of Beneficial Ownership

IOVA Stock Data

918.32M
295.51M
0.37%
80.63%
29.54%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SAN CARLOS